Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2611049 | 0.85 | PARP1 (0.46) | PARP1BRD4DRD4DRD3DRD2 | |
| SCHEMBL24351926 | 0.82 | PARP1 (0.44) | PARP1BRD4DRD4DRD3DRD2 | |
| SCHEMBL2497545 | 0.80 | PARP1 (0.50) | PARP1BRD4PRMT5 | |
| SCHEMBL18713659 | 0.79 | TSHR (0.42) | PARP1BRD4DRD4DRD3DRD2 | |
| SCHEMBL2127998 | 0.79 | PARP1 (0.41) | PARP1BRD4DRD4DRD3DRD2 | |
| SCHEMBL2820806 | 0.79 | PARP1 (0.56) | PARP1BRD4 | |
| SCHEMBL2127994 | 0.78 | HTR2A (0.47) | PARP1BRD4DRD4DRD3DRD2 | |
| SCHEMBL2496022 | 0.78 | PARP1 (0.41) | PARP1BRD4DRD4DRD3DRD2 | |
| SCHEMBL20032408 | 0.77 | PARP1 (0.42) | PARP1BRD4DRD4DRD3DRD2 | |
| SCHEMBL29117069 | 0.77 | PARP1 (0.43) | PARP1DRD4DRD3DRD2PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174583-A1 | PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES | DOW TECHNOLOGY INVESTMENTS LLC (US) | 2024-05-30 | — | — | US | disclosed |
| EP-4347544-A1 | PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES | Dow Technology Investments LLC (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2021032148-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2021-02-25 | — | — | WO | disclosed |
| EP-2970074-B1 | HYDROFORMYLATION PROVESS USING A HETEREOCYCLIC AGENT AS CATALYTIC STABILIZING AGENT | DOW TECHNOLOGY INVESTMENTS LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-9573870-B2 | Hetereocyclic agent as catalytic stabilizing agent in a hydroformylation process | DOW TECHNOLOGY INVESTMENTS LLC (US) | 2017-02-21 | — | — | US | disclosed |
| EP-2970074-A1 | HETEREOCYCLIC AGENT AS CATALYTIC STABILIZING AGENT IN A HYDROFORMYLATION PROCESS | Dow Technology Investments LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150376101-A1 | HETEREOCYCLIC AGENT AS CATALYTIC STABILIZING AGENT IN A HYDROFORMYLATION PROCESS | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY LLC | 2015-12-31 | — | — | US | disclosed |
| WO-2014149915-A1 | HETEREOCYCLIC AGENT AS CATALYTIC STABILIZING AGENT IN A HYDROFORMYLATION PROCESS | DOW TECHNOLOGY INVESTMENTS LLC (US) | 2014-09-25 | — | — | WO | disclosed |
| EP-0873292-B1 | IMPROVED METAL-LIGAND COMPLEX CATALYZED PROCESSES | UNION CARBIDE CHEM PLASTIC (US) | 2001-12-19 | — | — | EP | disclosed |
| EP-0873292-A1 | IMPROVED METAL-LIGAND COMPLEX CATALYZED PROCESSES | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1998-10-28 | — | — | EP | disclosed |
| US-5731472-A | HETEROCYCLIC NITROGEN COMPOUNDS | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1998-03-24 | — | — | US | disclosed |
| WO-1997020798-A1 | IMPROVED METAL-LIGAND COMPLEX CATALYZED PROCESSES | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1997-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376101-A1 | HETEREOCYCLIC AGENT AS CATALYTIC STABILIZING AGENT IN A HYDROFORMYLATION PROCESS | NUDT1, CAT, HRAS | PARP1 203/4885BRD4 2250/4885DRD4 2939/4885 |
| US-20240174583-A1 | PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES | ADH1C, ADH5, ALDH2 | PARP1 2414/4885BRD4 1339/4885DRD4 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.